pubmed-article:11277962 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11277962 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
pubmed-article:11277962 | lifeskim:mentions | umls-concept:C0037088 | lld:lifeskim |
pubmed-article:11277962 | lifeskim:mentions | umls-concept:C0332161 | lld:lifeskim |
pubmed-article:11277962 | lifeskim:mentions | umls-concept:C0157741 | lld:lifeskim |
pubmed-article:11277962 | lifeskim:mentions | umls-concept:C0908935 | lld:lifeskim |
pubmed-article:11277962 | lifeskim:mentions | umls-concept:C0599724 | lld:lifeskim |
pubmed-article:11277962 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
pubmed-article:11277962 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:11277962 | pubmed:dateCreated | 2001-3-30 | lld:pubmed |
pubmed-article:11277962 | pubmed:abstractText | Chronic idiopathic urticaria (CIU) is the most common type of chronic urticaria, and pruritus is the most prominent symptom. Antihistamines are the first-line treatment for CIU. Sedation and anticholinergic adverse effects are often experienced with the first-generation antihistamines and there is a risk of cardiovascular adverse effects and drug interactions with some second-generation agents. Hence, new treatment options are needed. Desloratadine is a new, potent, nonsedating antihistamine that has an excellent cardiovascular safety profile. | lld:pubmed |
pubmed-article:11277962 | pubmed:language | eng | lld:pubmed |
pubmed-article:11277962 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11277962 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:11277962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11277962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11277962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11277962 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11277962 | pubmed:month | Jan | lld:pubmed |
pubmed-article:11277962 | pubmed:issn | 0011-9059 | lld:pubmed |
pubmed-article:11277962 | pubmed:author | pubmed-author:MillerBB | lld:pubmed |
pubmed-article:11277962 | pubmed:author | pubmed-author:RingJJ | lld:pubmed |
pubmed-article:11277962 | pubmed:author | pubmed-author:HeinRR | lld:pubmed |
pubmed-article:11277962 | pubmed:author | pubmed-author:BronskyEE | lld:pubmed |
pubmed-article:11277962 | pubmed:author | pubmed-author:GaugerAA | lld:pubmed |
pubmed-article:11277962 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:11277962 | pubmed:volume | 40 | lld:pubmed |
pubmed-article:11277962 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11277962 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11277962 | pubmed:pagination | 72-6 | lld:pubmed |
pubmed-article:11277962 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:meshHeading | pubmed-meshheading:11277962... | lld:pubmed |
pubmed-article:11277962 | pubmed:year | 2001 | lld:pubmed |
pubmed-article:11277962 | pubmed:articleTitle | Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. | lld:pubmed |
pubmed-article:11277962 | pubmed:affiliation | Klinik und Poliklinik fur Dermatologie und Allergologie am Biederstein, Technische Universität München, München, Germany. | lld:pubmed |
pubmed-article:11277962 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:11277962 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:11277962 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:11277962 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:11277962 | pubmed:publicationType | Multicenter Study | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11277962 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11277962 | lld:pubmed |